2013 Archived Content
Fourth Annual

Cancer Biologics

Approaches Changing the Treatment of Cancer

 

Day 1Day 2 | Day 3

Friday, February 15

8:00 am Morning Coffee

 

Bi- and Multi-Specific Antibodies 

8:30 Chairperson's Remarks

Ivan D. Horak, M.D., F.A.C.P., CSO/CMO, R&D, Symphogen A/S

8:35 Improving Potency & Manufacturability of Bi-Specific Antibodies

Jason Baum, Ph.D., Principal Scientist, Research, Merrimack Pharmaceuticals, Inc.

Here we describe an optimization approach for multi-specific molecules targeting growth factor receptor signaling pathways that has been successfully applied to the design of MM-141, a stable high affinity bispecific antibody targeting IGF-1R and ErbB3.

9:05 Multi-Targeting Approaches in Oncology and Angiogenesis by Multi-Specific Darpins

Ulrike Fiedler, Ph.D., Principle Scientist, Disease Biology, Molecular Partners AG

This platform enables novel therapeutic concepts in which efficacy, PK, and mechanism of action are tailored to address unmet medical needs. We will highlight different pre-clinical programs.

9:35 BiTE® Antibodies for Cancer Therapy

Roman Kischel, M.D., Principal Scientist, BiTE Technology, Amgen Research (Munich) GmbH

10:05 Ang-2-VEGF Crossmab, a Novel Bi-specific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Function

Hubert Kettenberger, Ph.D., Principal Scientist, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH

CrossMabs represent a new class of bispecific, IgG-like antibodies which can be expressed in a single, stably transfected CHO cell line. A CrossMab against the angiogenesis factors VEGF-A and Ang-2, which has recently entered clinical trials, will be presented.

10:35 Coffee Break

11:00 Targeting Multiple Oncology Sites with Multi-Specific Antibody-Like Molecules

Peter Kiener, Ph.D., President & CEO, Zyngenia, Inc.

The Zybody platform generates multi-specific antibodies with 2-5 specificities that can simultaneously engage multiple targets. This can give rise to "better than additive" responses to modulation of cell growth and signaling receptors and internalization. We will discuss some examples.

11:30 Pre-Clinical Advances with a Fully Human Bispecific Antibody Platform

Eric Smith, Ph.D., Associate Director, Bispecific Antibodies, Regeneron Pharmaceuticals, Inc.

Using mouse genetic engineering platforms at Regeneron (Velocigene, VelocImmune) a novel platform technology has been established to generate fully human bi-specific antibodies. This presentation will describe recent pre-clinical results in in vitro and in vivo model systems.

12:00 pm Employing the Bispecific RECRUIT TandAb Platform

Uwe Reusche, Ph.D., Head, Bioassay Group, R&D, Affimed Therapeutics AG

This technology comprises CD3 RECRUIT and CD16 RECRUIT modules for respective T and NK cell recruitment and killing of cancer cells. We will report on safety and efficacy, and activity in the clinic.

12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

 

Combination Therapies 

1:45 Chairperson's Remarks

Ulrike Fiedler, Ph.D., Principle Scientist, Disease Biology, Molecular Partners AG

1:50 Combination Strategies to Enhance Anti-Tumor ADCC

Holbrook Kohrt, M.D., Ph.D., Assistant Professor, Oncology, University of Stanford

Here I discuss strategies that increase total target–monoclonal antibody–effector binding, strategies that trigger effector cell 'activating' signals, and strategies that block effector cell 'inhibitory' signals.

2:20 Observations with the ADC Trastuzumab Emtansine (T-DM1) Alone and in Combination

Steve Olsen, M.D., Ph.D., Global Development Team Leader, Trastuzumab Emtansine Product Development-Oncology, Genentech, Inc.

T-DM1 has demonstrated promising safety and efficacy as single-agent therapy for HER2-positive metastatic breast cancer. Combining T-DM1 with other HER2-directed therapy and/or chemotherapy has the potential to improve clinical efficacy. Pre-clinical and emerging clinical data will be discussed.

2:50 Novel Strategy to Target Tyrosine Kinase Receptors: From Bench to Clinic

Ivan D. Horak, M.D., F.A.C.P., CSO/CMO, R&D, Symphogen A/S

3:20 Close of Conference

Day 1Day 2 | Day 3

 

  2015 Plenary Sessions 

2015 MMTC Prelim Agenda 

Premier Sponsors:

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex 

Thomson Reuters-Large 


Local Partners:

BayBio 


biocube 


Cabs 

City of SSF